The distribution of BRCA1 and BRCA2 germ line mutations in breast/ovarian cancer families varies among different populations, which typically present a wide spectrum of unique mutations. Splicing mutation 5272-1G>A of BRCA1 and frameshift mutation 5374delTATG of BRCA2 are highly prevalent mutations in Castilla-León (Spain), accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively. To test the presence of founder effects, nine Spanish 5272-1G>A and thirteen 5374delTATG families were genotyped with polymorphic markers linked to BRCA1 or BRCA2. All the 5272-1G>A families shared a common haplotype in eight markers (1.1 Mb region) and the mutation age was estimated in 15 generations (~380 years). A conserved haplotype associated to 5374delTATG was observed in four markers (0.82 Mb). The mutation occurred approximately 48 generations ago (~1,200 years). Each mutation likely arose from a common ancestor that could be traced to a small area of Castilla-León and expanded to other Spanish regions. They can have significant impact on the clinical management of asymptomatic carriers as well as on the genetic screening strategy to be followed in populations with Spanish ancestries.
INTRODUCTION
Breast cancer is a multifactorial disease caused by interactions between genetic and non-genetic factors. Among 5-10% of all breast and ovarian cancers are considered hereditary, and about 30-50% of them are due to mutations in the two major susceptibility genes (BRCA1 and BRCA2) (1) (2) (3) . Approximately 3,500 distinct sequence variants have been described in the BIC database, of which more than 1,700 are pathogenic. Mutations are scattered along the entire coding regions and intronic flanking sequences of both genes. The frequency and incidence of mutations in these genes varies depending on the geographical area or the ethnic group.
However, several alterations have been identified in particular populations due to founder effects. To describe a recurrent mutation as a potential founder mutation, it is important to show that the mutation occurred only once in an ancestral individual or common ancestor. To distinguish between single and multiple historical occurrences of the same mutation, it is necessary to genotype DNA variants that are close enough to the mutation to cosegregate together through numerous generations, with little or no separation by meiotic recombination. Likewise, the identification of recombinant polymorphic markers in this study it is essential to estimate the number of generations since the mutation occurred.
Founder mutations have been described in individuals of distinct ancestries (4) including those observed in Ashkenazi Jews (187delAG and 5382insC of BRCA1 and 6174delT of BRCA2) (5), Iceland (BRCA2 995del5) (6) , and Portugal (BRCA2 c.156_157insAlu) (7, 8) , and other populations (9) (10) (11) . In the Spanish population mutations, 330A>G of BRCA1 from Northwestern Spain and 9254delATCAT from the Mediterranean region were described as founder mutations (12, 13) . The identification of founder mutations contributes to reduce the time and cost of the analysis providing an efficient design of the mutational screening protocols and genetic counselling in a specific population (14, 15) .
Since 1998, we have scanned for mutations the BRCA1 and BRCA2 genes in low to high risk breast/ovarian cancer patients within the Hereditary Breast and Ovarian Cancer (HBOC) prevention program of Castilla-León (Spain). In previous works we found that 65 out of 459 unrelated families carried a pathogenic mutation (23 BRCA1 and 42 BRCA2) (16) (17) (18) . We have completed the analysis in another 227 BOC families totalling 686 scanned families, where 104 positive families (15.2%; 38 BRCA1 and 66 BRCA2) were identified. The most frequent mutation of BRCA1 was 5272-1G>A (c.5153-1G>A according to the Human Genome Variation Society -HGVS-nomenclature) that was found in seven unrelated families (19) while 3036delACAA (HGVS nomenclature c.2808_2811delACAA) and 5374delTATG (HGVS c.5146_5149del4) were the most prevalent of BRCA2, that were detected in 12 and 9 families, respectively. BRCA1 5272-1G>A has been reported only five times in the BIC database or in Spanish families (20, 21) . This mutation causes an aberrant splicing of exon 19 by deletion of the first nucleotide, which generates a frameshift and a premature stop codon (20,21). The frameshift deletion 5374delTATG truncates the BRCA2 protein at codon 1723 and was described by our group for the first time although it has also been reported by other groups (17,20,22,23). By contrast, the 3036delACAA mutation has been described worldwide in many populations and is the second recurrent pathological mutation in the BIC database ranking. A previous work suggested that it may have multiple different origins (24).
In order to determine the presence of possible founder effects of mutations BRCA1 5272-1G>A and BRCA2 5374delTATG in Castilla-León we proceeded to study the haplotypes associated with them in our families and another two 5272-1G>A and four 5374delTATG families that were recruited from other Spanish regions.
.
MATERIALS AND METHODS

Patients
Breast and/or ovarian cancer patients from Castilla-León were selected according to the following criteria (16) 
BRCA1 and BRCA2 mutational analysis
Genomic DNA was isolated from peripheral blood lymphocytes by standard procedures. The complete coding sequences and the intron-exon boundaries of both genes were analyzed by Conformation Sensitive Gel Electrophoresis (CSGE) and Heteroduplex Analysis by Capillary Array Electrophoresis (HA-CAE) (25-27) (Supplemental Figures 1 and 2 13.6%) were the most prevalent alterations of BRCA2.
Haplotype generation and age estimation of 5272-1G>A
We typed seven families with the BRCA1 5272-1G>A mutation of the east of Castilla-León region and two additional Spanish positive families from the Basque Country and Valencia, one of them with confirmed origin in our region. This mutation is responsible of twelve breast cancer cases (two patients with bilateral BC) and two ovarian cancer cases (both with BC, too). The mean age of diagnosis is 49.9 years ranging from 23 to 76 years for breast cancer and 45.5 years for ovarian cancer (Table 1) . A total of 24 family members, 19 of them positive carriers, were available to establish the core haplotype.
We constructed the haplotype with six STR markers and four SNPs (Table 2 ; Figure 1 ). The DNA change 5194-53C>T were the most informative SNP as the disease-associated allele is only present in 12% of controls ( Table 2) . Six of the nine families share the haplotype 6-17-T-G-7-C-T-6-8-11. In three families (117, 178 and V-4), the disease-associated haplotype showed a recombination in one of the most distal flanking markers, D17S800 or D17S579. This common haplotype was found neither 150 control chromosomes nor non-carrier relatives. Furthermore, the frequencies of STR alleles of the core haplotype were lower than 15% in the control chromosomes, except for the D17S1323 microsatellite where the allele 6 was also the most prevalent in controls (63%).
The linkage disequilibrium measures (δ) between the mutation and each of the recombinant microsatellite markers D17S800 and D17S579 were calculated as δ= Haplotype generation and age estimation of 5374delTATG.
In the same way, BRCA2 5374delTATG mutation was detected in nine unrelated families from our region. Also, four Spanish families collected from Galicia, the Basque country, Catalonia and Madrid participated in this study. Clinical characteristics of these families are shown in Table 1 . Among the carriers there were twenty breast cancer cases (four of them bilateral and one male BC), two OC, four gastric and three prostate cancers among others ( Table 1 ). The average age of female BC cases was 47.1 years (ranging from 28 to 74 years old) and 67 years for OC. A total of 43 family members, 31 of them positive carriers, were used to construct the disease-associated haplotype.
Eight of the thirteen families carried a common haplotype associated to this mutation (9-2-12-2-C-3-6-5-3) ( Among families harbouring this mutation the ratio of breast cancer versus ovarian cancer is 6.5:1, which is in agreement with previous reports (34) that justify a lower proportion of ovarian cancer associated to mutations in the 3' region of the gene.
In East Castilla-León 5272-1G>A mutation was observed in seven unrelated families and is the most prevalent BRCA1 mutation (18.4%). Intriguingly, this mutation has not been identified in West Castilla-León (35). To date, this mutation has been detected in another three Spanish families outside Castilla-León (Figure 3) , one of them could not be included in this study. We confirmed that family BI-1 ( Interestingly, 5374delTATG is placed in the single-stranded portion of a hairpin-loop structure that is more vulnerable to spontaneous mutagenesis (Supplemental Figure   3 ) (40,41). Mutation 5272-1G>A is located in double-hairpin structure where the nucleotide 5272-1 is apparently a hotspot with two different changes: G to A and G to C. Furthermore, another important BIC mutations surrounding both, BRCA2
5298A>C and 5301insA (39 and 29 BIC entries, respectively), and BRCA1 5277A>G (15 BIC entries) are located in these "mutagenic" structures. These data suggest that most important mutations of the BRCA genes could have been generated by this mechanism.
In conclusion, each of these mutations likely arose from a common ancestor that could be traced to a small area of the provinces of Burgos and Palencia (539.253
inhabitants; shadowed in Figure 3 ). Both mutations are responsible for 27.6% of the 58 BRCA+ families from this specific area and the 5272-1G>A mutation alone is carried by 39% of BRCA1+ families (7/18 Another six BIC mutations of this DNA segment are shown. Origin of all of these mutations seems to be correlated with their presence in specific DNA secondary structures (single-stranded DNA, bulge loops or, specially,hairpin-loops) that are particularly vulnerable to mutagens. 
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